|
|
|
|
|
|
|
|
|
Monday May 23, 2005
|
|
8:00 am
|
|
|
I .
|
- Understand the juxtaposition between health plans and drivers in the pharmaceutical industry
- Analyze strategies to employ science (not marketing) to improve informed decision-making
- Adopt best practices from Wellpoint’s collaboration with CMS to mitigate risk
|
|
|
|
|
9:30 am
|
|
|
11:00 am
|
|
|
Robert Seidman
PharmD., MPH
Vice President and Chief Pharmacy Officer
WellPoint Inc.
|
| Dr. Robert Seidman is vice president and chief pharmacy officer for WellPoint Health Networks Inc. His responsibilities include drug use evaluation, pharmacy and therapeutics committee participation and medication education programs. He is also responsible for the management of all pharmacy related services and programs for WellPoint members enrolled in PPO, HMO, Medicare and Medi-Cal products nationwide. Since 1998, Dr. Seidman has led company efforts in petitioning the FDA to convert three prescription drug antihistamines (Claritin, Allegra and Zyrtec) to over-the-counter (OTC) status in an effort to increase member access to safe pharmaceuticals while reducing health care costs to consumers. Dr. Seidman’s career at the company began with the development and implementation of successful managed care pharmacy interventions for CaliforniaCare, the Blue Cross of California HMO. This year, the National Journal profiled him as one of 10 key thinkers who help to shape the nation’s drug pricing debate. Seidman has more than 15 years of pharmacy experience based in ambulatory, hospital and the managed care environment. The University of Southern California conveyed the doctor of pharmacy degree on Seidman in 1982, followed by his receiving a master’s degree in public health at the University of California, Los Angeles in 1983. |
|
|
|
|
|
|
|
|
 |
|
|